Fractalyser Limited

Prostate cancer is the 2nd most commonly occurring cancer in men and the 4th most common cancer overall. About 1 in 8 men will be diagnosed with prostate cancer during their lifetime. The standard procedure for its diagnosis is clinical history, a PSA blood test, followed by an MRI scan and finally, a biopsy. Despite their frequency, prostate biopsies remain expensive, painful, undignified affairs with limited diagnostic yield.

In current prostate cancer diagnostic procedures, as many as 50% of biopsies yield negative results, while up to 35% show false positives. Fractalyser offers a solution by utilising standard MRI imaging to non-invasively determine whether a prostate lesion warrants a biopsy, effectively addressing these issues. It does this by first conducting a “fractal analysis” of lesions detected on scans.